Application of a new human cell line, F2N78, in the transient and stable production of recombinant therapeutics

Biotechnology Progress

Volumn 29, Issue 2, 2013, Pages 432-440

  Lee, Hyun Joo ^a   Chang, Minseok ^a   Kim, Jong Mook ^a   Hong, Hyejin ^a   Maeng, Kieun ^a   Koo, Jane ^a   Chang, Shinjae ^a   Cho, Myung Sam ^a  

^a Celltrion Inc   (South Korea)

Author keywords

F2N78; Recombinant protein; Somatic hybrid; Stable production; Transient expression

Indexed keywords

EPSTEIN-BARR VIRUS; EXPRESSION VECTORS; F2N78; SOMATIC HYBRIDS; STABLE EXPRESSION; SUSPENSION CULTURES; THERAPEUTIC PROTEIN; TRANSIENT EXPRESSION;

CELL CULTURE; GENES; GENETIC ENGINEERING; PLANTS (BOTANY); RECOMBINANT PROTEINS; VIRUSES;

CELLS;

EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; RECOMBINANT PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL FUSION; CELL LINE; CYTOLOGY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN; KIDNEY; METABOLISM; PRENATAL DEVELOPMENT;

B-LYMPHOCYTES; CELL FUSION; CELL LINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION; HUMANS; KIDNEY; RECOMBINANT PROTEINS; TRANSFECTION;

HUMAN HERPESVIRUS 4;

EID: 84875954660     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1685     Document Type: Article

References (24)

1. Hossler P, Khattak SF, Jian Z. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009;19:936-949.
2. Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 2009;20:700-707.
3. Cho MS, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant protein production. J Biomed Sci. 2002;9:631-638.
4. Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu J, Subramanyam B, Fournel M, Pierce G, Murphy J. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116:270-279.
5. Fallaux FJ, Bout A, van der Velde I, van der Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9:1909-1917.
6. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten D, Logtenberg T, Bout A. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog. 2003;19:163-168.
7. Xie L, Pilbrough W, Metallo C, Zhong T, Pikus L, Leung J, Aunins JG, Zhou W. Serum-free suspension cultivation of PER.C6 cells and recombinant adenovirus production under different pH conditions. Biotechnol Bioeng. 2002;80:569-579.
8. Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J. Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol Bioeng. 2008;100:273-283.
9. Cho MS, Yee H, Brown C, Mei B, Mirenda C, Chan S. Versatile expression system for rapid and stable production of recombinant proteins. Biotechnol Prog. 2003;19:229-232.
10. Rabson M, Heston L, Miller G. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A. 1983;87:3660-3664.
11. Chang P, Shedd D, Gradoville L, Cho M, Chen L, Chang J, Miller G. Open reading frame 50 protein of Kaposi's sarcoma-associated Herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol. 2002;76:3168-3178.
12. Tellam J, Sherritt M, Thomson S, Tellam R, Moss D, Burrow SR, Wiertz E, Khanna R. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J Biol Chem. 2001;276:33353-33360.
13. Matsuo T, Heller M, Petti L, O'Shiro E, Kieff E. Peresistence of the Epstein-Barr virus genome integrated into human lymphocytes DNA. Science. 1984;226:1322-1325.
14. Gargano S, Caporossi D, Gualandi G, Calef E. Different localization of Epstein-Barr virus genome in two subclones of the Burkitt lymphoma cell line Namalwa. Genes, Chromosomes Cancer. 1992;4:205-210.
15. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176-180.
16. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005;21:11-16.
17. Kennett RH. Cell fusion. Methods Enzymol. 1979;58:345-359.
18. Fresen KO, Zur Hause H. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains. Int J Cancer. 1976;17:161-166.
19. Weintraub H, Genetta T, Kadesh T. Tissue-specific gene activation by MyoD: determination of specificity by cis-acting repression elements. Gene Dev. 1994;8:2203-3311.
20. Cole ES, Nichols EH, Poisson L, Harnois ML, Livingston DJ. In vitro clearance of tissue plasminogen-activator-the complex role of sites of glycosylation and level of sialylation. Fibrinolysis. 1993;7:15-22.
21. Flesher ER, Marzowski J, Wang WC, Raff HV. Fluorophore labeled glycan analysis of immunoglobulin fusion proteins: correlation of oligosaccharide content with in vivo clearance profile. Biotechnol Bioeng. 1995;46:399-407.
22. Lodish HF. Recognition of complex oligosaccharides by the multi-subunit asialoglycoprotein receptor. Trends Biochem Sci. 1991;16:374-377.
23. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acid Res. 2008;36:e96.
24. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev. 2006;58:671-685.